Hrvatska znanstvena bibliografija (CROSBI)

Pregled bibliografske jedinice broj: 119524

Zbornik radova

Autori: Huzjak, Nevenka; Barišić, Ingeborg; Rešić, Arnes; Vrdoljak, Javor; Kušec, Vesna; Antičević, Darko; Dodig, Damir; Primorac, Dragan
Naslov: Our experience in bisphosphonate therapy for osteogenesis imperfecta
( Our experience in bisphosphonate therapy for osteogenesis imperfecta )
Izvornik: 8th International Conference on osteogenesis imperfecta : abstractsAnnecy :
Skup: International Conference on osteogenesis imperfecta (8 ; 2002)
Mjesto i datum: Annecy, Francuska, 01.-03.09.2002.
Ključne riječi: osteogenesis imperfecta ; bisphosphonates
( osteogenesis imperfecta ; bisphosphonates )
Severe osteogenesis imperfecta (OI) is a hereditary disorder characterised by increased bone fragility and progressive bone deformity. Secondary osteoporosis is an important feature of OI. So far, no effective medical treatment is available. Antiresorptive acitivity of the aminobisphosphonates may improve clinical outcome in children. Aim was to assess the clinical impact of the administration of bisphosphonates in Croatian OI patients. We introduced therapy in 1998 encouraged by parents from Croatian Society of OI (HUOI). Here we report results of 1-4 years treatment with intravenous pamidronate (APD) in ten children (four girls) of age 3 months - 11 years at entry, with severe OI. Pamidronate was administered in cycles as monthly infusions at a daily dose of 1-1, 5 mg/kg during 6 months following pause for three months, or the same dose for three days every four months. All took 500-1000 mg calcium from food or supplements and 1000 IU of vitamin D daily. During treatment DEXA measurements showed a gradual increase in bone denisity in all paitents. Number of confirmed fractures decreased in all. The reduction in pain and imporvement in well-being and ability were impressive in two boys who had been confined to a wheelchair and now they walk using crutches. Well-known acute phase reactors were noted during first infusion cycle in two children and asymptomatic hypocalcaemia in three children. During the treatment three children gained weight compared to their height. Although the bisphosphonates do not correct basic abnormality in OI, they significantly alter the natural course of the disease and improve patients quality of life. For the time being they seem not only effective but also devoid of any adverse effects on bone growth and remodelling.
Vrsta sudjelovanja: Poster
Vrsta prezentacije u zborniku: Sažetak
Vrsta recenzije: Međunarodna recenzija
Projekt / tema: 0072165
Izvorni jezik: eng
Kategorija: Stručni
Znanstvena područja:
Javno zdravstvo i zdravstvena zaštita